Skip to content
Advertisement

FILE - A general view of AstraZeneca offices and the corporate logo in Cambridge, England, Saturday, July 18, 2020. AstraZeneca has recorded a big jump in revenue as it begins to take a profit from its coronavirus vaccine for the first time. The company recorded full-year revenues of $37.4 billion, an increase of 38% from the year before at constant exchange rates. Part of the boost came from $4 billion in sales of its COVID-19 vaccine, developed with the University of Oxford. Despite rising revenue, AstraZeneca reported a pre-tax loss of $265 million due to costs from its purchase of U.S. drug company Alexion Pharmaceuticals and new drug research. (AP Photo/Alastair Grant, File)

FILE - A general view of AstraZeneca offices and the corporate logo in Cambridge, England, Saturday, July 18, 2020. AstraZeneca has recorded a big jump in revenue as it begins to take a profit from its coronavirus vaccine for the first time. The company recorded full-year revenues of $37.4 billion, an increase of 38% from the year before at constant exchange rates. Part of the boost came from $4 billion in sales of its COVID-19 vaccine, developed with the University of Oxford. Despite rising revenue, AstraZeneca reported a pre-tax loss of $265 million due to costs from its purchase of U.S. drug company Alexion Pharmaceuticals and new drug research. (AP Photo/Alastair Grant, File)

Featured Photo Galleries